Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

RecruitingOBSERVATIONAL
Enrollment

198

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2026

Conditions
Combined Hepatocellular-cholangiocarcinomaCombined Hepatocellular Carcinoma and CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Interventions
COMBINATION_PRODUCT

Interventional therapies combined with or without systemic drugs

The study will include adult patients with histologically/cytologically confirmed unresectable CHC. Collect patient genomics, proteomics, immune microenvironment, pathology reports, medical images and clinical electronic medical records, etc., to form high-quality and deeply labeled data sets to support the subsequent development and application of AI large models. Based on multi-source heterogeneous data of CHC patients, a large model for comprehensive diagnosis and treatment was constructed. Firstly, multi-modal data of different stages of disease were integrated by using cross-modal multi-course fusion technology to achieve efficient fusion of complex data. Secondly, by fine-tuning the large model, tasks such as CHC classification, prognosis inference and treatment plan recommendation are accurately completed, and potential information in the diagnosis and treatment process is mined.

Trial Locations (1)

Unknown

RECRUITING

Zhongda Hospital, Nanjing

All Listed Sponsors
collaborator

Eastern Hepatobiliary Surgery Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Jiangsu Cancer Institute & Hospital

OTHER

collaborator

Yunnan Cancer Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Sun Yet-Sen University Cancer Center

OTHER

lead

Zhongda Hospital

OTHER